Biotechnology News and Research

RSS

AMRI reports $50.2 million total revenue for third quarter 2011

...

9 Nov 2011

Micromet's blinatumomab data to be reported at 53rd ASH annual meeting

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 - 13 in San Diego, California.

9 Nov 2011

Fluidigm third quarter total revenue increases 25% to $10.6 million

Fluidigm Corporation today announced its financial results for the third quarter ended September 30, 2011.

9 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

Bioject third quarter revenues increase to $3.1 million

Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today reported financial results for the third quarter ended September 30, 2011.

8 Nov 2011

Lapatinib drug could also treat head and neck cancers

A class of drugs used to treat breast cancers which overproduce a protein called HER2 could also treat other types of cancer - particularly head and neck cancers, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool this week.

8 Nov 2011

FDA grants Fast Track designation to Opexa's Tovaxin for treatment of SPMS

Opexa Therapeutics, Inc., announced today that its lead drug candidate Tovaxin® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Secondary Progressive Multiple Sclerosis.

8 Nov 2011

New results from BioCryst's BCX4208 Phase 2b gout study

BioCryst Pharmaceuticals, Inc. presents new results from its Phase 2b randomized, double-blind, dose-response study of BCX4208 in patients with gout who have failed to reach the clinically important serum uric acid (sUA) goal of <6 mg/dL on allopurinol alone.

8 Nov 2011

Polystyrene surface triples number of human ES and iPS cells in culture

By irradiating typical polystyrene lab plates with ultraviolet (UV) waves, Whitehead Institute and MIT scientists have created a surface capable of tripling the number of human embryonic stem (ES) and induced pluripotent stem (iPS) cells that can be grown in culture by current methods. Use of this novel surface also eliminates the need for layers of mouse "feeder cells" to support ES- and iPS-cell growth.

8 Nov 2011

Amgen plans $5 billion auction tender offer

Amgen today announced its plan to launch a modified Dutch auction tender offer to purchase up to $5 billion of its common stock, par value $0.0001 per share.

7 Nov 2011

HyQ phase III study data in patients with primary immunodeficiencies presented at ACAAI meeting

Baxter International Inc. today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI).

From Baxter International Inc. 7 Nov 2011

Transgenomic and A. Menarini Diagnostics enter distribution agreement for mutation detection systems

Transgenomic, Inc. and A. Menarini Diagnostics today announced an exclusive distribution agreement for Transgenomic's SURVEYOR Scan and WAVE MCE (Micro-Capillary Electrophoresis) Mutation Detection system to its network of over 2,000 pathologists throughout Europe.

7 Nov 2011

KYTHERA presents long-term results from ATX-101 Phase 2 study at ASDS 2011

KYTHERA Biopharmaceuticals, Inc., a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental fat.

7 Nov 2011

Electronic Nose can diagnose TB in symptomatic patients

A new hand-held device called the Electronic Nose, which has the potential to diagnose tuberculosis (TB) in symptomatic patients, was awarded a $950,000 grant from Grand Challenges Canada and the Bill & Melinda Gates Foundation today to support further development and testing of this ground-breaking technology.

7 Nov 2011

PKM2 enzyme has important non-metabolic functions in cancer formation

The embryonic enzyme pyruvate kinase M2 (PKM2) has a well-established role in metabolism and is highly expressed in human cancers. Now, a team led by researchers at the University of Texas MD Anderson Cancer Center reports in advance online publication of the journal Nature that PKM2 has important non-metabolic functions in cancer formation.

7 Nov 2011